Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Yale University UCB |
---|---|
Information provided by: | Yale University |
ClinicalTrials.gov Identifier: | NCT00291213 |
This is a placebo-controlled study designed to learn if levetiracetam is effective for tardive dyskinesia.
Condition | Intervention | Phase |
---|---|---|
Tardive Dyskinesia |
Drug: levetiracetam Drug: placebo |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria: meet Glazer Morgenstern criteria for TD -
Exclusion Criteria: none
-
United States, Connecticut | |
Connecticut Mental Health Center | |
New Haven, Connecticut, United States, 06519 |
Principal Investigator: | Scott W Woods, MD | Yale School of Medicine |
Study ID Numbers: | YaleHIC26585 |
Study First Received: | February 10, 2006 |
Last Updated: | February 10, 2006 |
ClinicalTrials.gov Identifier: | NCT00291213 |
Health Authority: | United States: Food and Drug Administration |
Signs and Symptoms Movement Disorders Neurologic Manifestations Central Nervous System Diseases |
Etiracetam Dyskinesias Tardive dyskinesia Oral facial dyskinesia |
Nootropic Agents Therapeutic Uses Nervous System Diseases |
Central Nervous System Agents Pharmacologic Actions Anticonvulsants |